Abstract:Rationale: Type 2 inflammation has been described in people with cystic fibrosis (CF). Whether loss of CFTR (cystic fibrosis transmembrane conductance regulator) function contributes directly to a type 2 inflammatory response has not been fully defined. Objectives: The potent alarmin IL-33 has emerged as a critical regulator of type 2 inflammation. We tested the hypothesis that CFTR deficiency increases IL-33 expression and/or release and deletion of IL-33 reduces allergen-induced inflammation in the CF lung. Methods: Human airway epithelial cells (AECs) grown from non-CF and CF cell lines and Cftr+/+ and Cftr-/- mice were used in this study. Pulmonary inflammation in Cftr+/+ and Cftr-/- mice with and without IL-33 or ST2 (IL-1 receptor-like 1) germline deletion was determined by histological analysis, BAL, and cytokine analysis. Measurements and Main Results: After allergen challenge, both CF human AECs and Cftr-/- mice had increased IL-33 expression compared with control AECs and Cftr+/+ mice, respectively. DUOX1 (dual oxidase 1) expression was increased in CF human AECs and Cftr-/- mouse lungs compared with control AECs and lungs from Cftr+/+ mice and was necessary for the increased IL-33 release in Cftr-/- mice compared with Cftr+/+ mice. IL-33 stimulation of Cftr-/- CD4+ T cells resulted in increased type 2 cytokine production compared with Cftr+/+ CD4+ T cells. Deletion of IL-33 or ST2 decreased both type 2 inflammation and neutrophil recruitment in Cftr-/- mice compared with Cftr+/+ mice. Conclusions: Absence of CFTR reprograms airway epithelial IL-33 release and licenses IL-33-dependent inflammation. Modulation of the IL-33/ST2 axis represents a novel therapeutic target in CF type 2-high and neutrophilic inflammation.

IL-1β Dominates the Promucin Secretory Cytokine Profile in Cystic Fibrosis

Involvement of Multiple Transcription Factors in Regulation of IL-β-induced MCP-1 Expression in Alveolar Type II Epithelial Cells.

Role of IL-1β in Experimental Cystic Fibrosis Upon P. Aeruginosa Infection.

Cystic Fibrosis Airway Mucus Hyperconcentration Produces a Vicious Cycle of Mucin, Pathogen, and Inflammatory Interactions That Promotes Disease Persistence.

Cystic Fibrosis Airway Secretions Exhibit Mucin Hyperconcentration and Increased Osmotic Pressure

Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL‐1 signaling pathway

Mucin Production and Hydration Responses to Mucopurulent Materials in Normal Versus Cystic Fibrosis Airway Epithelia

Airway IL-1β is related to disease severity and mucociliary function in bronchiectasis

Hyperconcentrated Mucus Unifies Submucosal Gland and Superficial Airway Dysfunction in Cystic Fibrosis

Airway Mucosal Host Defense is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity

IL-1β Upregulates Muc5ac Expression Via NF-κB-induced HIF-1α in Asthma.

Defective Postsecretory Maturation of Muc5b Mucin in Cystic Fibrosis Airways

Abnormal functional lymphoid tolerance and enhanced myeloid exocytosis are characteristics of resting and stimulated PBMCs in cystic fibrosis patients

Cystic Fibrosis Reprograms Airway Epithelial IL-33 Release and Licenses IL-33 Dependent Inflammation

Aberrant immune programming in neutrophils in cystic fibrosis

MUC5B regulates goblet cell differentiation and reduces inflammation in a murine COPD model

Macrophage PD-1 associates with neutrophilia and reduced bacterial killing in early cystic fibrosis airway disease

Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation

Altered O-glycosylation and Sulfation of Airway Mucins Associated with Cystic Fibrosis.

Flagellin Shifts 3D Bronchospheres Towards Mucus Hyperproduction

Contractile Properties of Intrapulmonary Airway Smooth Muscle in Cystic Fibrosis